Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Preferred Shares (2016 - 2025)

Guided Therapeutics' Preferred Shares history spans 13 years, with the latest figure at $18000.0 for Q4 2025.

  • On a quarterly basis, Preferred Shares fell 89.41% to $18000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $18000.0, a 89.41% decrease, with the full-year FY2025 number at $18000.0, down 89.41% from a year prior.
  • Preferred Shares hit $18000.0 in Q4 2025 for Guided Therapeutics, down from $32000.0 in the prior quarter.
  • Over the last five years, Preferred Shares for GTHP hit a ceiling of $1.6 million in Q4 2021 and a floor of $18000.0 in Q4 2025.
  • Historically, Preferred Shares has averaged $471684.2 across 5 years, with a median of $475000.0 in 2023.
  • Biggest five-year swings in Preferred Shares: soared 698.1% in 2023 and later plummeted 93.26% in 2025.
  • Tracing GTHP's Preferred Shares over 5 years: stood at $1.6 million in 2021, then plummeted by 70.16% to $489000.0 in 2022, then skyrocketed by 71.37% to $838000.0 in 2023, then tumbled by 79.71% to $170000.0 in 2024, then tumbled by 89.41% to $18000.0 in 2025.
  • Business Quant data shows Preferred Shares for GTHP at $18000.0 in Q4 2025, $32000.0 in Q2 2025, and $61000.0 in Q1 2025.